Detalhe da pesquisa
1.
The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
Br J Haematol
; 204(5): 1649-1659, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38362778
2.
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Br J Haematol
; 204(2): 525-533, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37905734
3.
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Blood
; 140(1): 38-44, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35421218
4.
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
Eur J Haematol
; 112(3): 371-378, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879842
5.
Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals.
J Antimicrob Chemother
; 78(6): 1454-1459, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37051877
6.
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Haematologica
; 108(1): 110-121, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770532
7.
Evaluation of cell collection efficiency in non-mobilized adult donors for autologous chimeric antigen receptor T-cell manufacturing.
Vox Sang
; 118(3): 217-222, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36516201
8.
Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease.
Am J Hematol
; 97(6): 731-739, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35253928
9.
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies.
Mol Ther
; 29(2): 636-644, 2021 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010231
10.
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.
Clin Cancer Res
; 30(10): 2085-2096, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38466644
11.
Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?
Br J Haematol
; 183(1): 127-129, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28832940
12.
Chemotherapy resistant Burkitt lymphoma: Possible novel therapies including CAR-T cell infusion.
Clin Case Rep
; 11(6): e7361, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37260617
13.
Characterization of the endotheliopathy, innate-immune activation and hemostatic imbalance underlying CAR-T cell toxicities: laboratory tools for an early and differential diagnosis.
J Immunother Cancer
; 11(4)2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37045474
14.
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Front Immunol
; 14: 1303935, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38187393
15.
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
Transplant Cell Ther
; 29(7): 430-437, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37031746
16.
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Bone Marrow Transplant
; 58(6): 673-679, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918682
17.
Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing.
Front Immunol
; 13: 1005457, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36238283
18.
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation.
Front Oncol
; 12: 828471, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35174095
19.
Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients.
Free Neuropathol
; 32022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37284165
20.
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.
Front Immunol
; 13: 855730, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35911769